Stock-Based Compensation	12 Months Ended
Dec. 31, 2021
Stock-Based Compensation [Abstract]
Stock-Based Compensation	NOTE 12 - STOCK BASED COMPENSATION At the Annual Meeting held on April 22, 2014, the Company’s stockholders approved the Norwood Financial Corp 2014 Equity Incentive Plan. An aggregate of 375,000 shares of authorized but unissued Common Stock of the Company were reserved for future issuance under the Plan. This includes up to 60,000 shares for awards to outside directors. The Plan also authorized the Company to award restricted stock to officers and outside directors, limited to 63,000 shares of restricted stock awards for officers and 12,000 shares of restricted stock awards for outside directors. At the Annual Meeting held on April 24, 2018, the Company’s stockholders approved an amendment to the 2014 Equity Incentive Plan to ease certain restrictions on restricted stock awards to outside directors. As a result of this amendment, the number of shares available for restricted stock awards to officers was reduced by 300 shares to 62,700, while the number of shares available for restricted stock awards to outside directors was increased by 20,300 to 32,300 shares. Under this plan, the Company granted 296,966 shares, which included 191,865 options to employees, 10,400 options to directors, 62,625 shares of restricted stock to officers and 32,075 shares of restricted stock to directors. The restricted shares vest over five years. The product of the number of shares granted and the grant date market price of the Company’s common stock determine the fair value of restricted stock under the company’s restricted stock plan. Management recognizes compensation expense for the fair value of restricted stock on a straight-line basis over the requisite service period for the entire award. As of December 31, 2021, there were 78,035 shares available for future awards under this plan, which includes 60,510 shares available for officer awards and 17,525 shares available for awards to outside directors. Included in these totals are 75 shares available for restricted stock awards to officers and 25 shares available for restricted stock awards to outside directors. Total unrecognized compensation cost related to stock options was $269,000 as of December 31, 2021 and $214,000 as of December 31, 2020. Salaries and employee benefits expense includes $214,000 and $204,000 of compensation costs related to options for the years ended December 31, 2021 and 2020, respectively. Compensation costs related to restricted stock amounted to $335,000 and $334,000 for the years ended December 31, 2021 and 2020, respectively. The expected future compensation expense relating to non-vested restricted stock outstanding as of December 31, 2021 and 2020 was $953,000 and $1,202,000, respectively. A summary of the Company’s stock option activity and related information for the years ended December 31 follows: 2021 2020 Weighted Weighted Average Average Average Average Exercise Intrinsic Exercise Intrinsic Options Price Value Options Price ValueOutstanding, beginning of year 215,970 $ 25.73 199,825 $ 24.78 Granted 43,500 25.80 33,750 26.93 Exercised (22,420) 17.59 (15,530) 17.25 Forfeited (10,975) 29.48 (2,075) 16.83 Outstanding, end of year 226,075 $ 26.37 $ 520 215,970 $ 25.73 $ 742,738 Exercisable, end of year 182,575 $ 26.50 $ 511 182,220 $ 25.51 $ 742,738 Exercise prices for options outstanding as of December 31, 2021 ranged from $17.93 to $36.02 per share. The weighted average remaining contractual life is 6.4 years. The fair value of each option grant is estimated on the date of grant using the Black-Scholes option pricing model with the following weighted average assumptions: Years Ended December 31, 2021 2020Dividend yield 3.55% 3.55%Expected life 10 years 10 yearsExpected volatility 34.69% 34.15%Risk-free interest rate 1.51% 0.91%Weighted average fair value of options granted$ 6.49 $ 6.34 The expected volatility is based on historical volatility. The risk-free interest rates for periods within the contractual life of the awards are based on the U.S. Treasury yield curve in effect at the time of the grant. The expected life is based on historical exercise experience. The dividend yield assumption is based on the Company’s history and expectation of dividend payouts. Proceeds from stock option exercises totaled $394,000 in 2021. Shares issued in connection with stock option exercises are issued from available treasury shares or from available authorized shares. During 2021, for the shares issued in connection with stock option exercises, 22,420 shares in total, all shares were issued from available authorized shares. As of December 31, 2021, outstanding stock options consist of the following: Average Average Options Exercise Remaining Options Exercise Outstanding Price Life, Years Exercisable Price 21,450 $ 18.03 1.0 21,450 $ 18.03 1,650 18.36 1.0 1,650 18.36 19,375 17.93 2.0 19,375 17.93 8,250 19.39 2.9 8,250 19.39 9,375 19.03 3.9 9,375 19.03 14,375 22.37 5.0 14,375 22.37 26,750 32.81 6.0 26,750 32.81 23,600 32.34 7.0 23,600 32.34 24,000 36.02 8.0 24,000 36.02 33,750 26.93 9.0 33,750 26.93 1,000 26.35 9.3 — — 1,000 25.38 9.5 — — 41,500 25.80 9.9 — — Total 226,075 182,575 A summary of the Company’s restricted stock activity and related information for the years ended December 31 is as follows: 2021 2020 Weighted-Average Weighted-Average Number of Grant Date Number of Grant Date Shares Fair Value Shares Fair ValueNon-vested, beginning of year 39,135 $30.72 36,195 $31.65Granted 8,000 25.80 14,500 26.93Vested (11,205) 32.15 (11,560) 32.89Forfeited (3,900) 31.72 — —Non-vested at December 31 32,030 $26.76 39,135 $30.72

Stock-Based Compensation

12 Months Ended

Dec. 31, 2021

NOTE 12 - STOCK BASED COMPENSATION At the Annual Meeting held on April 22, 2014, the Company’s stockholders approved the Norwood Financial Corp 2014 Equity Incentive Plan. An aggregate of 375,000 shares of authorized but unissued Common Stock of the Company were reserved for future issuance under the Plan. This includes up to 60,000 shares for awards to outside directors. The Plan also authorized the Company to award restricted stock to officers and outside directors, limited to 63,000 shares of restricted stock awards for officers and 12,000 shares of restricted stock awards for outside directors. At the Annual Meeting held on April 24, 2018, the Company’s stockholders approved an amendment to the 2014 Equity Incentive Plan to ease certain restrictions on restricted stock awards to outside directors. As a result of this amendment, the number of shares available for restricted stock awards to officers was reduced by 300 shares to 62,700, while the number of shares available for restricted stock awards to outside directors was increased by 20,300 to 32,300 shares. Under this plan, the Company granted 296,966 shares, which included 191,865 options to employees, 10,400 options to directors, 62,625 shares of restricted stock to officers and 32,075 shares of restricted stock to directors. The restricted shares vest over five years. The product of the number of shares granted and the grant date market price of the Company’s common stock determine the fair value of restricted stock under the company’s restricted stock plan. Management recognizes compensation expense for the fair value of restricted stock on a straight-line basis over the requisite service period for the entire award. As of December 31, 2021, there were 78,035 shares available for future awards under this plan, which includes 60,510 shares available for officer awards and 17,525 shares available for awards to outside directors. Included in these totals are 75 shares available for restricted stock awards to officers and 25 shares available for restricted stock awards to outside directors. Total unrecognized compensation cost related to stock options was $269,000 as of December 31, 2021 and $214,000 as of December 31, 2020. Salaries and employee benefits expense includes $214,000 and $204,000 of compensation costs related to options for the years ended December 31, 2021 and 2020, respectively. Compensation costs related to restricted stock amounted to $335,000 and $334,000 for the years ended December 31, 2021 and 2020, respectively. The expected future compensation expense relating to non-vested restricted stock outstanding as of December 31, 2021 and 2020 was $953,000 and $1,202,000, respectively. A summary of the Company’s stock option activity and related information for the years ended December 31 follows: 2021 2020 Weighted Weighted Average Average Average Average Exercise Intrinsic Exercise Intrinsic Options Price Value Options Price ValueOutstanding, beginning of year 215,970 $ 25.73 199,825 $ 24.78 Granted 43,500 25.80 33,750 26.93 Exercised (22,420) 17.59 (15,530) 17.25 Forfeited (10,975) 29.48 (2,075) 16.83 Outstanding, end of year 226,075 $ 26.37 $ 520 215,970 $ 25.73 $ 742,738 Exercisable, end of year 182,575 $ 26.50 $ 511 182,220 $ 25.51 $ 742,738 Exercise prices for options outstanding as of December 31, 2021 ranged from $17.93 to $36.02 per share. The weighted average remaining contractual life is 6.4 years. The fair value of each option grant is estimated on the date of grant using the Black-Scholes option pricing model with the following weighted average assumptions: Years Ended December 31, 2021 2020Dividend yield 3.55% 3.55%Expected life 10 years 10 yearsExpected volatility 34.69% 34.15%Risk-free interest rate 1.51% 0.91%Weighted average fair value of options granted$ 6.49 $ 6.34 The expected volatility is based on historical volatility. The risk-free interest rates for periods within the contractual life of the awards are based on the U.S. Treasury yield curve in effect at the time of the grant. The expected life is based on historical exercise experience. The dividend yield assumption is based on the Company’s history and expectation of dividend payouts. Proceeds from stock option exercises totaled $394,000 in 2021. Shares issued in connection with stock option exercises are issued from available treasury shares or from available authorized shares. During 2021, for the shares issued in connection with stock option exercises, 22,420 shares in total, all shares were issued from available authorized shares. As of December 31, 2021, outstanding stock options consist of the following: Average Average Options Exercise Remaining Options Exercise Outstanding Price Life, Years Exercisable Price 21,450 $ 18.03 1.0 21,450 $ 18.03 1,650 18.36 1.0 1,650 18.36 19,375 17.93 2.0 19,375 17.93 8,250 19.39 2.9 8,250 19.39 9,375 19.03 3.9 9,375 19.03 14,375 22.37 5.0 14,375 22.37 26,750 32.81 6.0 26,750 32.81 23,600 32.34 7.0 23,600 32.34 24,000 36.02 8.0 24,000 36.02 33,750 26.93 9.0 33,750 26.93 1,000 26.35 9.3 — — 1,000 25.38 9.5 — — 41,500 25.80 9.9 — — Total 226,075 182,575 A summary of the Company’s restricted stock activity and related information for the years ended December 31 is as follows: 2021 2020 Weighted-Average Weighted-Average Number of Grant Date Number of Grant Date Shares Fair Value Shares Fair ValueNon-vested, beginning of year 39,135 $30.72 36,195 $31.65Granted 8,000 25.80 14,500 26.93Vested (11,205) 32.15 (11,560) 32.89Forfeited (3,900) 31.72 — —Non-vested at December 31 32,030 $26.76 39,135 $30.72